Literature DB >> 14529779

Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy.

Gunar K Zagars1, Matthew T Ballo, Peter W T Pisters, Raphael E Pollock, Shreyaskumar R Patel, Robert S Benjamin.   

Abstract

PURPOSE: To document the prognostic factors for survival of patients with soft-tissue sarcoma sustaining a first relapse after definitive treatment. METHODS AND MATERIALS: The clinicopathologic features, relapse patterns, and disease-specific survival rates for 402 consecutive patients sustaining a first relapse of sarcoma after combined surgery and radiotherapy were retrospectively reviewed. Factors affecting disease-specific survival after relapse were evaluated with univariate and multivariate techniques.
RESULTS: The median follow-up after relapse was 6.8 years. The overall disease-specific survival rate was 25%, 19%, and 16% at 5, 10, and 15 years, respectively, after the first relapse. The median survival duration was 21 months. Patients with an isolated local recurrence had a 5- and 10-year disease-specific survival rate of 48% and 46%, respectively, and those with an initial metastatic relapse had a disease-specific survival rate of 16% and 10%, respectively (p < 0.001). For isolated local recurrences, the independent determinants of survival were (favorable feature first) the primary tumor site (extremity and superficial trunk vs. head and neck and deep trunk); tumor grade (low and intermediate vs. high); time to recurrence (>12 vs. <or =12 months); and initial tumor size (<or =5 vs. >5 cm). Although the development of subsequent metastasis was the major cause of death, a significant fraction of patients died of uncontrolled primary tumor. For patients presenting with metastasis as the first relapse, the time to metastasis was the major determinant of survival (>12 vs. < or =12 months). Long-term salvage was largely confined to patients who could and did undergo resection of relapsed disease, either local or metastatic.
CONCLUSION: On the whole, patients whose sarcoma relapses fare poorly. However, select subgroups are potentially salvageable. Patients with an isolated local recurrence at sites other than the head and neck and deep trunk have a reasonable prospect for satisfactory outcome. Surgical resection of recurrences and metastases appears to play a major role in potential salvage.

Entities:  

Mesh:

Year:  2003        PMID: 14529779     DOI: 10.1016/s0360-3016(03)00714-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma.

Authors:  Nicholas P Gannon; Matthew H Stemm; David M King; Meena Bedi
Journal:  J Cancer Res Clin Oncol       Date:  2019-03-07       Impact factor: 4.553

Review 2.  [Soft tissue sarcoma: how can posttreatment alterations be distinguished from recurrences?]

Authors:  I-M Noebauer-Huhmann; T Grieser
Journal:  Radiologe       Date:  2017-11       Impact factor: 0.635

3.  Primary superficial femoral vein leiomyosarcoma: report of a case.

Authors:  Dimitrios Yfadopoulos; Dimitrios Nikolopoulos; Evanthia Novi; Antonios Psaroudakis
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

4.  Local recurrence after initial multidisciplinary management of soft tissue sarcoma: is there a way out?

Authors:  Sarantis Abatzoglou; Robert E Turcotte; Abdurahman Adoubali; Marc H Isler; David Roberge
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

Review 5.  Multidisciplinary management of soft tissue sarcomas.

Authors:  Ángel Montero Luis; Damián Pérez Aguilar; José Antonio López Martín
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.405

6.  Impact of disease free status on prognosis in metastatic non-small round cell soft tissue sarcomas.

Authors:  Hiroshi Urakawa; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Clin Exp Metastasis       Date:  2016-09-07       Impact factor: 5.150

Review 7.  Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma.

Authors:  Antoine Digonnet; Marc Hamoir; Guy Andry; Vincent Vander Poorten; Missak Haigentz; Johannes A Langendijk; Remco de Bree; Michael L Hinni; William M Mendenhall; Vinidh Paleri; Alessandra Rinaldo; Jochen A Werner; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-26       Impact factor: 2.503

Review 8.  [Surgical treatment of musculoskeletal soft tissue sarcomas].

Authors:  M Rudert; R Burgkart; R Gradinger; H Rechl
Journal:  Chirurg       Date:  2009-03       Impact factor: 0.955

9.  Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Schmid; Christoph H Saely
Journal:  Clin Exp Metastasis       Date:  2007-10-12       Impact factor: 5.150

10.  Circulating tumour-derived DNA in metastatic soft tissue sarcoma.

Authors:  Nicholas C Eastley; Barbara Ottolini; Rita Neumann; Jin-Li Luo; Robert K Hastings; Imran Khan; David A Moore; Claire P Esler; Jacqueline A Shaw; Nicola J Royle; Robert U Ashford
Journal:  Oncotarget       Date:  2018-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.